Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView.

Exclusion Criteria

• •The participant had previously received 123 I-mIBG or 131 I-mIBG.
• •The participant had known or suspected hypersensitivity/allergy to iodine, Iobenguane or to any of the excipients in AdreView.
• •The participant had a heart transplant at any time prior to enrollment.
• •The participant had LVEF \>35% as measured by an appropriate method (e.g., radionuclide or contrast ventriculography, ECG-gated SPECT MPI, MR, CT, or echocardiography) within 30 days prior to enrollment into the study.
• •The participant had received defibrillation either external or via an implantable cardioverter defibrillator (ICD), anti-tachycardia pacing, or cardioversion to treat an arrhythmic event in the previous 90 days.
• •The participant had a cardiac revascularization, insertion of an ICD, or acute myocardial infarction within 30 days before study entry.
• •The participant used any of the following medications: Amitriptyline and derivatives, imipramine and derivatives, other antidepressants that inhibit the norepinephrine transporter, antihypertensives that deplete norepinephrine stores or inhibit reuptake, sympathomimetic amines and cocaine.
• •The participant had either NYHA Class I or NYHA Class IV HF at the time of study entry.
• •The participant had renal insufficiency (creatinine \>3 mg/dl).
• •The participant had participated in a clinical trial involving IMP or devices within 30 days prior to first administration of AdreView™.
• •In the investigator's opinion, the participant's medical history included either extensive lifetime exposure to ionizing radiation (medical, occupational, other) or documented total radiation dose \>50 mSv during the previous 5 years.
• •The participant had experienced HF hospitalization, increased HF symptoms without hospitalization, or had a change or increase in HF medications during the previous 3 months.
• •The participant had a serious non-cardiac medical condition associated with significant elevation of plasma catecholamines, including pheochromocytoma.